Biotech Values

[ThomasS]

ANDS: Between ANA 380 for HBV and ANA 975 for HCV, I don't know how IDIX can effectively compete, especially in the HCV space against other competitors. Their HBV drug already faces challengers...

"These Phase II data are significant and very encouraging, and suggest that ANA380 may very well be the best-in-class among marketed HBV therapies and product candidates in development," said Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Anadys. "We and our LG Life Sciences partner look forward to both the next clinical milestones and advancing our business discussions with Novartis on this program."

"We are very pleased with ANA380's promising clinical results and believe they emphasize ANA380's potential as the next generation therapy for HBV patients," said In-Chull Kim, Ph.D., President and Chief Executive Officer of LG Life Sciences.

I sold IDIX.